NO–Steroids: Potent Anti-inflammatory Drugs with Bronchodilating Activity in Vitro

Tallet, Dominique; Soldato, Piero Del; Oudart, Nicole; Burgaud, Jean-Luc

doi:10.1006/bbrc.2001.6192

Cited by 23 publications

(15 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…NO containing steroid moiety in its structure may provide useful anti-infl ammatory drugs along with bronchodilating property. (Tallet et al, 2002).…”

Section: No In Lung Infl Ammatory Disordersmentioning

confidence: 99%

Role of nitric oxide in inflammatory diseases

2007

View full text Add to dashboard Cite

Nitric oxide (NO) is a signaling molecule that plays a key role in the pathogenesis of inflammation. It gives an anti-inflammatory effect under normal physiological conditions. On the other hand, NO is considered as a pro-inflammatory mediator that induces inflammation due to over production in abnormal situations. NO is synthesized and released into the endothelial cells by the help of NOSs that convert arginine into citrulline producing NO in the process. Oxygen and NADPH are necessary co-factors in such conversion. NO is believed to induce vasodilatation in cardiovascular system and furthermore, it involves in immune responses by cytokine-activated macrophages, which release NO in high concentrations. In addition, NO is a potent neurotransmitter at the neuron synapses and contributes to the regulation of apoptosis. NO is involved in the pathogenesis of inflammatory disorders of the joint, gut and lungs. Therefore, NO inhibitors represent important therapeutic advance in the management of inflammatory diseases. Selective NO biosynthesis inhibitors and synthetic arginine analogues are proved to be used for the treatment of NO-induced inflammation. Finally, the undesired effects of NO are due to its impaired production, including in short: vasoconstriction, inflammation and tissue damage.

show abstract

“…NO containing steroid moiety in its structure may provide useful anti-infl ammatory drugs along with bronchodilating property. (Tallet et al, 2002).…”

Section: No In Lung Infl Ammatory Disordersmentioning

confidence: 99%

Role of nitric oxide in inflammatory diseases

2007

View full text Add to dashboard Cite

show abstract

“…A NO-releasing moiety has now been attached to budesonide, dexamethasone and hydrocortisone to produce their respective NODD. All of these NO-releasing steroid derivatives possessed more potent anti-inflammatory activity than their parent compounds and were coupled with a concentration-dependent bronchodilator activity in vitro (Tallet et al, 2002). The data obtained is sufficiently encouraging to propose that NO-steroids may be able to alleviate the symptoms of asthma in vivo.…”

Section: Bronchial Asthmamentioning

confidence: 82%

Application of pharmaceuticals to nitric oxide

Low

2005

Molecular Aspects of Medicine

View full text Add to dashboard Cite

“…All agents were added in a cumulative manner into the organ bath. At the end of the experiment, papaverine (10 −4 M), a nonspecific phosphodiesterase inhibitor, was added to the organ bath to induce a maximal relaxation as an internal reference to show the unimpaired tissue [15].…”

Section: Methodsmentioning

confidence: 99%

“…In the 9th, 10th, 11th, and 12th sets, tissues were separately exposed to 10 −4 M NOR-4 (control and ovalbumin-sensitized) and 10 −5 M ODQ + 10 −4 M NOR-4 (control and ovalbumin-sensitized) after incubation with 10 −6 M carbachol for 15 minutes in a tissue bath. In the thirteenth and fourteenth sets, tissues were separately exposed to 10 −4 M T-0156 (control and ovalbumin-sensitized) after incubation with 10 −6 M carbachol for 15 …”

Section: Measurement Of Cgmp Levels In Trachea Preparationsmentioning

confidence: 99%

Role of new agents affecting NO/cGMP pathway on ovalbumin-sensitized guinea pig trachea

Parlak

Yıldırım

Bağcıvan

et al. 2012

Experimental Lung Research

View full text Add to dashboard Cite

Asthma is a chronic inflammatory disease in which cell components play important roles. We aimed to evaluate the effects of NO/cGMP cleavage at trachea preparations isolated from ovalbumin-sensitized guinea pigs in vitro. Trachea rings were exposed to 3-ethyl-3-(ethylaminoethyl)-1-hydroxy-2-oxo-1-triazene (NOC-12), (±)-(E)-4-ethyl-2-[(Z)-hydroxyimino]-5-nitro-3-hexen-1-yl-nicotinamide (NOR-4), 2-(2-methylpyridin-4-yl)methyl-4-(3,4,5-trimethoxyphenyl)-8-(pyrimidin-2-yl) methoxy-1,2-dihydro-1-oxo-2,7-naphthyridine-3-carboxylic acid methyl ester hydrochloride (T-0156), and electrical field stimulation (EFS). cGMP levels in trachea tissues were also measured. The relaxation responses of NOC-12, NOR-4, T-0156, and EFS were significantly decreased at ovalbumin-sensitized group. Nitric oxide (NO) donors significantly decreased the relaxation responses in the presence of 1H-[1,2,4] oxadiazolo [4,3-a] quinoxalin-1-one (ODQ). L-Nitro-Arginine Methyl Ester (L-NAME) significantly decreased the EFS relaxation responses in both groups (experimental group and control group), but this effect was reversed by L-Arginine addition. In the experimental group, cGMP levels after EFS, carbachol, NOC-12, NOR-4, and T-0156 exposure were significantly lower than control group. In both groups, cGMP levels after NO donors' exposure were significantly lower in the presence of ODQ and the cGMP levels after EFS + L-NAME were significantly lower than EFS alone. These results may show the increased formation of NO because of the increased iNOS activity in airway sensitization leading to the inhibition of cNOS resulting in the decrease of endogen NO and decrease of activation of guanylyl cyclase.

show abstract

NO–Steroids: Potent Anti-inflammatory Drugs with Bronchodilating Activity in Vitro

Cited by 23 publications

References 24 publications

Role of nitric oxide in inflammatory diseases

Role of nitric oxide in inflammatory diseases

Application of pharmaceuticals to nitric oxide

Role of new agents affecting NO/cGMP pathway on ovalbumin-sensitized guinea pig trachea

Contact Info

Product

Resources

About